Cash/Burn From SEC Filing For Period: 

Q1 '20

HGEN

Humanigen, Inc.

Humanigen, Inc. is a clinical-stage biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization and gene-knockout platforms.

Cash

$0.5

Burn Rate

-$2.5

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Lenzilumab

COVID-19

Phase 3 (Interim Analysis)

September 2020

Lenzilumab

Relapsed or Refractory Diffuse Large B-Cell Lymphoma / RR DLBCL

Phase 1b (Results)

Q4 2020

Ifabotuzumab | KB004

Glioblastoma Multiforme (GBM)

Phase 1

H1 2021

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon